Identification of a Novel Activation-inducible Protein of the Tumor Necrosis Factor Receptor Superfamily and Its Ligand*

Byungsuk KwonDagger **, Kang-Yeol YuDagger **, Jian Ni§, Guo-Liang Yu§, Ihn-Kyung JangDagger , Young-June KimDagger , Lily Xing§, Ding Liu§, Shu-Xia Wang§, and Byoung S. KwonDagger parallel Dagger Dagger

From the Dagger  Department of Microbiology and Immunology and the Walther Oncology Center, Indiana University School of Medicine and the Walther Cancer Institute, Indianapolis, Indiana 46202, § Human Genome Sciences, Rockville, Maryland 20850, and the Dagger Dagger  Department of Biological Sciences and the Immunomodulation Research Center, University of Ulsan, Ulsan, Korea

    ABSTRACT
Top
Abstract
Introduction
References

Among members of the tumor necrosis factor receptor (TNFR) superfamily, 4-1BB, CD27, and glucocorticoid-induced tumor necrosis factor receptor family-related gene (GITR) share a striking homology in the cytoplasmic domain. Here we report the identification of a new member, activation-inducible TNFR family member (AITR), which belongs to this subfamily, and its ligand. The receptor is expressed in lymph node and peripheral blood leukocytes, and its expression is up-regulated in human peripheral mononuclear cells mainly after stimulation with anti-CD3/CD28 monoclonal antibodies or phorbol 12-myristate 13-acetate/ionomycin. AITR associates with TRAF1 (TNF receptor-associated factor 1), TRAF2, and TRAF3, and induces nuclear factor (NF)-kappa B activation via TRAF2. The ligand for AITR (AITRL) was found to be an undescribed member of the TNF family, which is expressed in endothelial cells. Thus, AITR and AITRL seem to be important for interactions between activated T lymphocytes and endothelial cells.

    INTRODUCTION
Top
Abstract
Introduction
References

Members of the TNFR1 superfamily share similar multiple cysteine-rich pseudorepeats of the extracellular domain, each containing 30-45 amino acids with six cysteines (1). Except for the death domain-containing family, which includes TNFR1 (2), Fas (3-5), DR3 (6-9), DR4 (10-12), DR5 (13-17), and decoy TNF-related apoptosis-inducing ligand (TRAIL) receptors (18-21), no remarkable similarity is found within the intracellular domain of these molecules. However, there is a striking homology in the cytoplasmic domains of murine and human 4-1BB, CD27, and murine GITR within TNFR superfamily members (22-24). Acidic amino acids are especially highly conserved in the cytoplasmic domain of this subfamily. Like other TNFR superfamily members (1), this subfamily is implicated in diverse biological functions. First of all, 4-1BB and CD27 molecules provide strong co-stimulatory signals for T cell proliferation when ligated with their respective ligands or with agonistic antibodies (1, 25). In addition to functioning as an accessory molecule, CD27 induces apoptosis, which is mediated by a death domain-containing molecule called Siva (26). Recently identified murine GITR is shown to inhibit T cell receptor-induced apoptosis (24).

Although the immunological functions of subfamily members have been relatively well defined, insights into their signal transduction pathway have only recently been revealed (27-30). Two groups (27, 28) have provided data indicating that association of 4-1BB with TRAF2 molecules initiates a signal cascade leading to activation of NF-kappa B. In the CD27 signaling pathway, both TRAF2 and TRAF5 mediate NF-kappa B and SAPK/JNK (stress-activated protein kinase/c-Jun N-terminal kinase) activation, and NIK (NF-kappa B-inducing kinase) is a common downstream kinase of TRAF2 and TRAF5 (30).

Because the number of TNFR members is rapidly expanding, we expected that even more numbers of the superfamily would exist. By searching an EST (expressed sequence tag) data base, we identified a new member of the TNFR and its ligand. Here we give an initial characterization of the receptor and its ligand.

    EXPERIMENTAL PROCEDURES

cDNA Cloning-- A data base containing more than 2 million ESTs obtained from over 750 different cDNA libraries was generated by Human Genome Sciences, Inc., using high throughput automated DNA sequence analysis of randomly selected human cDNA clones. A specific homology and motif search using the known amino acid sequence and motif of TNFR members against this data base revealed several ESTs with a translated sequence 35-55% homologous to that of the TNFR family. Several clones were identified from cDNA libraries of PHA-activated T cells, T helper cells, leukocytes, a healing abdomen wound, primary dendritic cells, and adipose tissue. A full-length AITR cDNA clone encoding an intact N-terminal signal peptide was obtained from a human activated T cell library and selected for further investigation. The complete cDNA sequence of both strands of this clone was determined, and its homology to TNFR members was confirmed. Similarly, TL6 (TNF ligand 6) was identified through a systematic comparison of sequence homology with TNF ligand family members. Partial TL6 sequences, which were 25% homologous to that of TNF ligand family members, were identified from endothelial, HUVEC (human umbilical vein endothelial cell), brain, and fetal liver cDNA libraries. A full-length cDNA clone was obtained from a human brain cDNA library.

Expression Vectors-- Full-length and HA (hemagglutinin A epitope)-tagged AITR encoding the putative entire AITR protein (amino acids 26-234) were amplified by PCR using sense (5'-CTAGCTAGCTAGVVVAGCGCCCCACCGGGGGTCCC-3', and 5'-CTAGCTAGCTAGCTATCCATATGATGTTCCAGATTATGCTCAGCGCCCCACCGGGGGTCCC-3', respectively) and antisense (5'-AAGGAAAAAAGC GGGCCGCTCACACCCACAGGTCTCCCAG-3') primers, cut with NheI/NotI, and fused in-frame downstream of a CD5 leader sequence (28) into the pcDNA3.1 (pcDNA3.1/CD5L-AITR) and pcDNA3 (pcDNA3/CD5L-AITR), respectively. Full-length TL6 was amplified by PCR (sense, 5'-AGACCCAAGCTTTT GAAAATGA TATGAGACGC-3'; antisense, 5'-AGACGGGATCCTCCTCCTATAG TAAGAAGGC-3'), cut with HindIII/BamHI, and inserted into pcDNA3.1 (pcDNA3.1/TL6) and pCEP4 (Invitrogen, Carlsbad, CA; pCEP4/TL6). pRK5-based expression vectors encoding Flag-tagged full-length TRAF1, TRAF2, TRAF3, TRAF5, TRAF6, NIK, dominant negative TRAF2 (dnTRAF2), or dnNIK have been described (28, 31-36). The NF-kappa B-dependent E-selectin-luciferase reporter gene (pELAM-Luc) and pRSV-beta galactosidase (pRSV-beta -gal) plasmids were also described elsewhere (31, 37).

Northern Blot and RT (Reverse Transcriptase)-PCR Analysis-- For Northern blot analysis, cDNA probes were labeled with 32P using the Rediprime DNA labeling system (Amersham Pharmacia Biotech), according to the manufacturer's instructions. Unincorporated nucleotide was removed from the labeled probe using CHROMA SPIN-100 (CLONTECH). Two human multiple tissue poly(A) RNA blots containing approximately 2 µg of poly(A) RNA per lane from various human tissues were purchased from CLONTECH. In addition, two cell line blots containing 20 mg of total RNA from different cell lines were used. Northern blotting was performed with the Expressed Hybridization Solution (CLONTECH) according to the manufacturer's manual. For RT-PCR analysis, total RNA was isolated from human PBMC after stimulation with dexamethasone, PMA/ionomycin, or anti-CD3/CD28 mAbs and from unstimulated or LPS-stimulated HUVEC cells. RT-PCR was performed under standard conditions.

Interaction of AITR with TRAFs-- pcDNA3/CD5L-AITR-HA plasmid (5 µg/10 cm-plate) was co-transfected into HEK293 EBNA cells (2 × 106 cells/plate) by the standard calcium phosphate precipitation method with pRK/TRAF1, -2, -3, -5, or -6-Flag vector (5 µg/plate). Twenty four hours after transfection, cells were lysed with 1 ml of lysis buffer (50 mM HEPES (pH 7.4), 250 mM NaCl, 0.1% Nonidet P-40, 5 mM EDTA, 10% glycerol, and protease inhibitors). For immunoprecipitation, lysates were incubated with anti-Flag M2 (Eastman Kodak Co.) or control murine IgG1 mAb at 4 °C for 1 h, followed by incubation with 20 µl of a 1:1 slurry of protein G-Sepharose (PharMingen, San Diego, CA) for another hour. Precipitates were thoroughly washed with lysis buffer, then fractionated on a 10% SDS-polyacrylamide gel before transfer to polyvinylidene difluoride membrane (Millipore). Western blot analysis was performed with anti-HA mAb coupled with horseradish peroxidase (Boehringer Mannheim) and visualized using the enhanced chemiluminescence Western blotting detection system (Amersham Pharmacia Biotech).

Analysis of NF-kappa B by Reporter Assay-- Approximately 0.5 × 106 HEK293 EBNA cells/well were seeded on 6-well plates. After 24 h, cells were transfected by the standard calcium phosphate precipitation method using various combinations of pcDNA3.1/CD5L-AITR plus pRK5 plasmids encoding TRAFs, dnTRAF2, NIK, or dnNIK. The total amount of plasmid was adjusted to 2.0 µg by adding empty vector. Twenty-four hours after transfection, cells were lysed in 200 µl of reporter lysis buffer (Promega, Madison, WI). Luciferase activity was measured using 20 µl of cell extract. 5 µl of cell extract was used to assay beta -galactosidase activity as an internal control, and luminescence values were normalized by individual beta -galactosidase activity.

Recombinant Protein Production and Purification-- AITR-Fc fusion protein was used for ligand screening and cell-binding experiments. A fragment encoding the predicted extracellular domain of AITR (amino acids 26-139) was amplified using a sense primer flanked by an NheI site (5'-AGACCCAAGCTTGTGGGCTCTTGAAA CCCGGCATG-3') and an antisense primer flanked by a BglII site (5'-GAAAGATCT GGGCTCTGCCGGCGGGGACCCTGGGAC-3'). The amplified fragment was cut with NheI/BglII and cloned into mammalian vector pCEP4, in-frame with CD5L at the 5' end and with the Fc portion of human IgG1 at the 3' end (pCEP4/CD5L-AITR-Fc). pCEP4/CD5L-AITR-Fc was transfected into HEK293 EBNA cells. AITR-Fc fusion protein was purified from pCEP4/CD5L-AITR-Fc-transfected HEK293 EBNA cell supernatants using the protein G column. To generate a Flag-tagged soluble form of TL6 protein (amino acids 39-169), the Flag-tagged TL6 expression vector (pCEP4/CD5L-TL6-Flag) was constructed by PCR amplification of TL6 coding sequences using sense (5'-CTAGCTAGCCCAGCGCCCCGACTACAAGGA CGACGATGACAAGGAGACT GCTAAGGAGCCC-3') and antisense (5'-CCGCTC GAGCTATAGTAAGAAGGCTCC-3') primers, digesting the product with NheI/XhoI, and cloning into pCEP4, in-frame with the CD5L sequence. The construct was expressed in HEK293 EBNA cells. Transfected cell supernatants containing secreted TL6-Flag were harvested and used for binding assays. For some experiments, TL6-Flag protein was purified from harvested supernatants, using anti-Flag gel (Sigma) according to the manufacturer's instructions.

Binding Assay-- Protein binding assays were done essentially as described (12). For cell-binding assays, HEK293 EBNA cells were transfected using pcDNA3.1/CD5L-AITR or pcDNA3.1, as described above. Forty-eight hours after transfection, cells were harvested and incubated consecutively with TL6-Flag-containing supernatant, anti-Flag antibody, and FITC-conjugated anti-mouse IgG antibody (Southern Biotechnology, Birmingham, AL). Flow cytometry analysis was performed using the Becton Dickinson FACScan (San Jose, CA). Jurkat T cells were stably transfected by electroporation using linearized pcDNA3.1/CD5L-AITR and selected in the presence of Zeocin (Invitrogen). A binding assay for this cell line was performed as described above. To test the ability of AITR-Fc fusion protein to bind membrane-bound TL6, pCEP4/TL6 was stably transfected into HEK293 EBNA cells. After selection in the presence of hygromycin, TL6-expressing cells were harvested and incubated with AITR-Fc protein, followed by FITC-conjugated anti-human IgG1 antibody (Southern Biotechnology). The Becton Dickinson FACScan was used for flow cytometry analysis.

    RESULTS AND DISCUSSION

AITR was identified by searching an EST data base. A full-length cDNA of a clone from a human activated T-cell cDNA library, which is tentatively named AITR (for activation-inducible TNFR family member), encodes a 234-amino acid type I transmembrane protein with a calculated molecular mass of 25 kDa (Fig. 1A). The receptor has a signal peptide (the first 25 amino acids) and a single transmembrane region (amino acids 140-158). When compared with the extracellular domain of other TNFR family members, AITR displays three cysteine-rich pseudorepeats corresponding to the second, third, and fourth TNFR motif, respectively. The first cysteine pseudorepeat contains eight cysteine residues and lacks C4. Therefore, it is unlikely that the canonical pattern of C1-C2, C3-C5, and C4-C6 disulfide bridges exist in this motif. The second pseudorepeat shows some features of the third TNFR motif, but it is atypical in that C5 is not present even though it contains 7 cysteine residues. The third pseudorepeat shows extensive homologies with the fourth pseudorepeat of 4-1BB. The cytoplasmic domain contains acidic amino acids that are highly conserved in the cytoplasmic domains of 4-1BB, CD27, and GITR. Overall, AITR exhibits a high homology (55% identity) to murine GITR (Fig. 1B), but there is a mismatch in the first cysteine-rich pseudorepeat between GITR and AITR, because the first pseudorepeat of GITR corresponds to the first TNFR cysteine-rich motif (24).


View larger version (57K):
[in this window]
[in a new window]
 
Fig. 1.   Sequence and expression analysis of AITR. A, deduced amino acid sequence of AITR. The potential signal sequence is underlined. The putative glycosylation site is indicated as bold characters, and the transmembrane region is indicated in boxes. B, comparison of the amino acid sequence of AITR with murine GITR. Bold letter cs within three cysteine pseudorepeat motifs indicate conserved cysteine residues found in the extracellular domain of TNFR superfamily members. Conserved acidic amino acid clusters of the cytoplasmic domain are indicated in boxes. C, expression of AITR: Northern blot analysis in various tissues and cancer cell lines (left panels) and RT-PCR analysis in human PBMC (right panels). Northern blots of poly(A) RNA from human tissues and cancer cell lines were analyzed by hybridization to a 32P-labeled cDNA probe containing the entire AITR coding regions. For RT-PCR, 2.0 × 106 human PBMC were activated by treatment with different stimuli (dexamethasone (Dex), PMA/ionomycin (P/I), or alpha CD3/alpha CD28 mAbs) for 24 and 48 h. Total RNA was extracted using TriZOL. 1 µg of total RNA was used for reverse transcriptase and PCR reaction. beta -Actin was amplified as an internal control.

We investigated expression of AITR mRNA in multiple human tissues by Northern blot hybridization (Fig. 1C). 1.25-kilobase mRNA was detected in lymph node, peripheral blood leukocytes, and, weakly, in spleen. We also tested a variety of tumor cell lines for expression of AITR mRNA (Fig. 1C). A 1.25-kilobase message was detected only in the colorectal adenocarcinoma cell line, SW480, among the cell lines tested. The expression of virtually all members of the TNFR superfamily is enhanced by antigen stimulation/lymphocyte activation (1). Consistent with this idea, AITR expression was up-regulated in PBMC after stimulation. No AITR message was detectable in unstimulated PBMC when we used a sensitive RT-PCR method (Fig. 1C). AITR expression was clearly induced within 24 h by typical PBMC stimulation such as treatment with PMA plus ionomycin or soluble anti-CD3 plus anti-CD28 mAbs. FACS analysis for AITR expression, however, showed that a small population of activated PBMC expressed AITR on the cell surface at 48 h after stimulation, suggesting that a prolonged period of stimulation is required for maximum expression of AITR.2 Expression of AITR was not induced by treatment with dexamethasone. This property was different from that of GITR (24).

Recently it has been shown that 4-1BB molecules associate with TRAF1, TRAF2, and TRAF3 (27-29). Because the cytoplasmic domain of AITR is similar to that of 4-1BB, we tested its ability to co-precipitate five of the six known TRAFs that were overexpressed in HEK293 EBNA cells. We observed an interaction of AITR with TRAF1, TRAF2, and TRAF3 but not with TRAF5 and TRAF6 (Fig. 2A). The association of AITR with TRAF2 suggested that, like other members of the TNFR superfamily (27, 28, 30, 31, 39-41), AITR might mediate NF-kappa B activation through TRAF2. To test this possibility, we used an NF-kappa B reporter system in HEK293 EBNA cells (31). Co-transfection with the AITR expression vector typically induced greater than 3-fold higher luciferase activity when compared with the vector transfection control (Fig. 2, B and C). When co-expressed with TRAF2, AITR induced greater luciferase activity than did TRAF2 alone (Fig. 2, B and C). More importantly, overexpression of dominant-negative TRAF2, which lacked the RING and zinc finger motifs (31), abrogated the luciferase activity induced by AITR (Fig. 2B). This indicates that TRAF2 is an important mediator of NF-kappa B activation for AITR. A similar observation was made when we blocked the activity of NIK, which was thought to lie downstream of TRAF2 in the NF-kappa B signaling pathway, by overexpression of the dominant-negative NIK (36), which lacked the two lysine residues of the catalytic domain (Fig. 2B). Taken together, these data indicate that AITR mediates NF-kappa B activation through the TRAF2/NIK pathway. Since TRAF1 and TRAF3 were found to associate with AITR in HEK293 EBNA cells, we examined the effects of TRAF1 and TRAF3 on NF-kappa B activation induced by AITR. As shown in Fig. 2C, introduction of TRAF3 nearly abolished the luciferase activity induced by AITR overexpression. To a lesser extent, TRAF1 overexpression diminished AITR-induced NF-kappa B activation. These data suggest that TRAF1 and especially TRAF3 down-regulate AITR-induced NF-kappa B activation.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 2.   AITR associates TRAF1, TRAF2, and TRAF3 and induces NF-kappa B activation through TRAF2. A, interaction of AITR with TRAF1, TRAF2, and TRAF3. HEK293 EBNA cells (2 × 106) were transfected with expression vector for HA-tagged AITR plus Flag-tagged TRAF1, TRAF2, TRAF3, TRAF5, or TRAF6. After 24 h, cell lysates were immunoprecipitated with murine control IgG1 (c) or anti-Flag (alpha F) mAb. Co-precipitated HA-tagged AITR protein was detected by immunoblot analysis with anti-HA mAb. B, overexpression of dnTRAF2 or dnNIK abrogates NF-kappa B activation induced by AITR. HEK293 EBNA cells were transfected with pELAM-Luc reporter plasmid, pRSV-beta -gal, and indicated combinations of expression vectors for AITR, TRAF2, dnTRAF2, NIK, dnNIK, or an empty vector. Luciferase activities were measured after 24 h and normalized on the basis of beta -galactosidase activity levels. Values are presented as mean ± S.E. C, TRAF1 and TRAF3 play a down-modulatory role in NF-kappa B activation induced by AITR. Experiments were performed in the same conditions described above. Each experiment was done in triplicate, and the data presented are representative of three or more independent experiments.

To identify AITRL, we screened a panel of Flag-tagged candidate TNF ligand proteins for binding to AITR-Fc fusion protein by immunoprecipitation. AITR-Fc selectively bound TL6-Flag among Flag-tagged TNF ligand proteins tested (Fig. 3A). In our experimental conditions, 4-1BB and TR2 (HVEM) bound their cognate ligands, 4-1BBL and LIGHT (38), respectively (data not shown). Furthermore, our data clearly showed that TL6-Flag protein bound AITR transiently expressed on the cell surface of HEK293 EBNA cells and AITR constitutively expressed on the cell surface of Jurkat cell (Fig. 3B, upper and middle panels, respectively). Since TL6 is a transmembrane protein (see below), we used flow cytometry to determine whether AITR-Fc fusion protein was able to bind HEK293 EBNA cells that were stably transfected with full-length TL6. We found that AITR-Fc protein was capable of binding TL6 expressed on HEK293 EBNA cells (Fig. 3B, lower panel). Next, we tested whether interactions between AITR and TL6 would result in NF-kappa B activation. In an NF-kappa B reporter assay, ligand-dependent NF-kappa B activation was demonstrated by co-transfecting transmembrane TL6 with AITR (data not shown) or transfecting TL6-expressing HEK293 EBNA cells (Fig. 3C). In addition, when AITR was transiently transfected into HEK293 EBNA cells, which constitutively secreted soluble TL6 protein, NF-kappa B activation markedly increased as compared with empty vector-tansfected HEK293 EBNA cells (Fig. 3C). Similarly, higher NF-kappa B activation was induced by treating with soluble TL6 protein HEK293 cells that were transiently transfected with AITR (data not shown). This indicates that TL6 is able to trigger AITR-specific activation of NF-kappa B. It appears that higher induction of NF-kappa B by TL6 is correlated with a stronger association of AITR with TRAF2 in HEK293 EBNA cells, since stronger association of AITR with TRAF2 was observed in cells that were co-transfected with TL6 than in cells that were transfected with AITR alone.2


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 3.   TL6 is the ligand for AITR. A, the extracellular domain of AITR selectively bound TL6. AITR-Fc protein was incubated with supernatants containing TL3-, LIGHT-, TL6-, TL7-, or 4-1BBL-Flag protein (DNA sequences of TL3 and TL7 not published). AITR-Fc·ligand complexes were precipitated with protein G-Sepharose and resolved on a 10% SDS-polyacrylamide gel. Bound ligand was identified by immunoblot. B, FACS analysis of AITR-TL6 interactions. Upper panel, HEK293 EBNA cells were transfected with pcDNA3/CD5L-AITR or an empty vector using the calcium phosphate method. Forty-eight hours after transfection, cells were harvested with 10 mM EDTA in phosphate-buffered saline, incubated with supernatant containing TL6-Flag, and stained with anti-Flag antibody, followed by FITC-conjugated secondary antibody. Middle panel, AITR-transfected and parental Jurkat cells were similarly stained as described above. AITR mRNA was detected in transfectant (AITR) but not in parental (P) cells by RT-PCR (inset). Lower panel, HEK293 EBNA cells were transfected with pCEP4/TL6 or an empty vector using the calcium phosphate method. After selection in the presence of hygromycin, cells were harvested with 10 mM EDTA in phosphate-buffered saline, incubated with AITR-Fc fusion protein, and stained with FITC-conjugated anti-human IgG1 antibody. Expression of TL6 mRNA was confirmed in transfectant cells (inset). C, AITR/TL6-mediated NF-kappa B activation. HEK293 EBNA cells, which were stably transfected with an empty vector (pCEP4), a full-length TL6 (pCEP4/TL6), or a Flag-tagged AITR extracellular domain construct (pCEP4/CD5L-AITR-Flag) were transfected with the pELAM-Luc reporter plasmid, pRSV-beta -gal, and indicated combinations of expression vectors for AITR or an empty vector. Luciferase activities were measured after 24 h and normalized on the basis of beta -galactosidase activity levels. Values are presented as mean ± S.E. Each experiment was done in triplicate, and the data presented are representative of three independent experiments.

TL6 was one of the TNF ligand proteins initially identified by an EST data base search. Hydrophilicity analysis of a full-length TL6 clone from a brain cDNA library predicts a single hydrophobic transmembrane domain and the absence of a signal sequence (Fig. 4A). TL6 contains two potential glycosylation sites in the C-terminal region. These features suggest that TL6 is a type II membrane protein with the C-terminal region extracellular. Northern blot analysis of human tissue RNAs revealed expression of a single 2.4-kilobase TL6 mRNA in pancreas (Fig. 4B). Various human cell lines and PBMC were also examined for TL6 expression. No message was detectable in either unstimulated or stimulated T-cell lines (CEM-6 and Jurkat), B-cell lines (Priess and Frev), promyelocytic cell line (HL-60), monocytic cell line (THP-1), and PBMC by RT-PCR (data not shown). In contrast, HUVEC cells constitutively expressed TL6, and its expression was up-regulated after stimulation with LPS (Fig. 4B). Therefore, it is speculated that AITR and its ligand are important for interactions between activated T lymphocytes and blood vessels.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 4.   Sequence and expression analysis of TL6. A, deduced amino acid sequence of TL6. The potential transmembrane domain is underlined, and the putative glycosylation sites were indicated as bold characters. B, expression of TL6 in human tissues and HUVEC cells. Northern blots of poly(A) RNA from human tissues (left panel) were analyzed by hybridization to a 32P-labeled cDNA probe containing the entire TL6 coding regions. RT-PCR was performed using 1 µg of total RNA extracted from unstimulated or LPS-stimulated HUVEC cells (right panel). beta -Actin was amplified as an internal control.

AITR has 55% identity with murine GITR at the amino acid level. The high sequence conservation between human and mouse provides evidence that AITR is the human homologue of murine GITR. At this point, however, the possibility remains that these two receptors may serve distinct functions from one another, based on the following facts. 1) There is a mismatch in the first cysteine-rich pseudorepeat between GITR and AITR; 2) in contrast to GITR, AITR is not inducible by dexamethasone.

In summary, we have identified a novel protein of the TNFR superfamily, AITR, which activates NF-kappa B through a TRAF2-mediated mechanism. Expression of AITR is activation-inducible. The ligand for AITR is a member of the TNF ligand family and is constitutively expressed in an endothelial cell line. This indicates that AITR and its ligand may be involved in activated T cell trafficking.

    ACKNOWLEDGEMENTS

We thank Sister Mary Etta Kiefer and Pat Mantel for editing the manuscript.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants AI28125 and DE12156 and Molecular Medicine Program 98-mm-02-01-A-04 from the Ministry of Science and Technology, Korea.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF117297 and AF117713.

Present address: Mendel Biotechnology, Inc., Hayward, CA 94545.

parallel To whom correspondence should be addressed: Dept. of Microbiology and Immunology, Indiana University School of Medicine, 635 Barnhill Dr., Indianapolis, IN 46202. Tel.: 317-274-3950; Fax: 317-274-4090; E-mail: kkwon{at}sunflower.bio.indiana.edu.

** These two authors contributed equally to this work.

2 B. Kwon, unpublished data.

    ABBREVIATIONS

The abbreviations used are: TNFR, tumor necrosis factor receptor; AITR, activation-inducible TNFR family member; GITR, glucocorticoid-induced TNFR family-related gene; PMBC, peripheral mononuclear cells; TRAF, TNF receptor-associated factor; mAb, monoclonal antibody; PHA, phytohemagglutinin; HA, hemagglutinin; EST, expressed sequence tag; PMA, phorbol 12-myristate 13-acetate; HUVEC, human umbilical vein endothelial cell; RT, reverse transcriptase; PCR, polymerase chain reaction; LPS, lipopolysaccharide(s); NIK, NF-kappa B-inducing kinase; dn, dominant negative; FITC, fluorescein isothiocyanate.

    REFERENCES
Top
Abstract
Introduction
References
  1. Smith, C. A., Farrah, T., and Goodwin, R. G. (1994) Cell 76, 959-962[Medline] [Order article via Infotrieve]
  2. Schall, T. J., Lewis, M., Koller, K. J., Lee, A., Rice, G. C., Wong, G. H. W., Gatanaga, T., Granger, G. H., Lentz, R., Raab, H., Kohr, W. J., and Goeddel, D. V. (1990) Cell 61, 361-370[Medline] [Order article via Infotrieve]
  3. Trauth, B. C., Klas, C., Peters, A. M., Matzku, S., Moller, P., Falk, W., Debatin, K. M., and Krammer, P. H. (1989) Science 245, 301-305[Medline] [Order article via Infotrieve]
  4. Yonehara, S., Ishii, A., and Yonehara, M. (1989) J. Exp. Med. 169, 1747-1756[Abstract]
  5. Oehm, A., Behrmann, I., Falk, W., Pawlita, M., Maier, G., Klas, C., Li-Weber, M., Richards, S., Dhein, J., Trauth, B. C., Ponsting, H., and Krammer, P. H. (1992) J. Biol. Chem. 267, 10709-10715[Abstract/Free Full Text]
  6. Chinnaiyan, A. M., O'Rourke, K., Yu, G.-L., Lyons, R. H., Garg, M., Duan, D. R., Xing, L., Gentz, R., and Dixit, V. M. (1996) Science 274, 990-992[Abstract/Free Full Text]
  7. Kitson, J., Raven, T., Jiang, Y.-P., Goeddel, D. V., Giles, K. M., Pun, K. T., Grinham, C. J., Brown, R., and Farrow, S. N. (1996) Nature 384, 372-375[CrossRef][Medline] [Order article via Infotrieve]
  8. Bodmer, J.-L., Burns, K., Schneider, P., Hofmann, K., Steiner, V., Thome, M., Bornand, T., Hahne, M., Schroter, M., Becker, K., Wilson, A., French, L. E., Browing, J. L., MacDonald, H. R., and Tschopp, J. (1997) Immunity 6, 79-88[Medline] [Order article via Infotrieve]
  9. Screaton, G. R., Xu, X.-N., Olsen, A. L., Cowper, A. E., Tan, R., McMichael, A. J., and Bell, J. I. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4615-4619[Abstract/Free Full Text]
  10. Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C. P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., and Goodwin, R. G. (1995) Immunity 3, 673-682[Medline] [Order article via Infotrieve]
  11. Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., and Ashkenaz, A. (1996) J. Biol. Chem. 271, 12687-12690[Abstract/Free Full Text]
  12. Pan, G., O'Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., and Dixit, V. M. (1997) Science 276, 111-113[Abstract/Free Full Text]
  13. Walczak, H., Degli-Esposti, M. A., Johnson, R. S., Smolak, P. J., Waugh, J. Y., Boiani, N., Timour, M. S., Gerhart, M. J., Schooley, K. A., Smith, C. A., Goodwin, R. G., and Rauch, C. T. (1997) EMBO J. 16, 5386-5397[Abstract/Free Full Text]
  14. MacFarlane, M., Ahmad, M., Srinivasula, S. M., Fernandes-Alnemri, T., Cohen, G. M., and Alnemri, E. S. (1997) J. Biol. Chem. 272, 25417-25420[Abstract/Free Full Text]
  15. Schneider, P., Thome, M., Burns, K., Bodmer, J.-L., Hofmann, K., Kataoka, T., Holler, N., and Tschopp, J. (1997) Immunity 7, 831-836[Medline] [Order article via Infotrieve]
  16. Chaudhary, P. M., Eby, M., Jasmin, A., Bookwaller, A., Murray, J., and Hood, L. (1997) Immunity 7, 821-830[Medline] [Order article via Infotrieve]
  17. Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, I., Gray, C. L., Baker, K., Wood, W. I., Goddard, A. D., Godowski, P., and Ashkenazi, A. (1997) Science 277, 818-821[Abstract/Free Full Text]
  18. Marsters, S. A., Sheridan, J. P., Pitti, R. M., Huang, A., Skubatch, M., Baldwin, D., Yuan, J., Gurney, A., Goddard, A. D., Godowski, P., and Ashkenazi, A. (1997) Curr. Biol. 7, 1003-1006[Medline] [Order article via Infotrieve]
  19. Pan, G., Ni, J., Wei, Y.-F., Yu, G.-L., Gentz, R., and Dixit, V. M. (1997) Science 277, 815-818[Abstract/Free Full Text]
  20. Degli-Esposti, M. A., Smolak, P. J., Walczak, H., Waugh, J., Huang, C.-P., DuBose, R. F., Goodwin, R. G., and Smith, C. A. (1997) J. Exp. Med. 186, 1165-1170[Abstract/Free Full Text]
  21. Degli-Esposti, M. A., Dougall, W. C., Smolak, D. J., Waugh, J. Y., Smith, C. A., and Goodwin, R. G. (1997) Immunity 7, 813-820[Medline] [Order article via Infotrieve]
  22. Kwon, B. S., and Weissmann, S. M. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 1963-1967[Abstract]
  23. Camerimi, D., Walz, G., Loenen, W. A. M., Borst, J., and Seed, B. (1991) J. Immunol. 147, 3165-3169[Abstract/Free Full Text]
  24. Nocentini, G., Giunchi, L., Ronchetti, S., Krausz, L. T., Bartoli, A., Moraca, R., Migliorati, G., and Riccardi, C. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 6216-6221[Abstract/Free Full Text]
  25. Pollok, K. E., Kim, Y.-J., Zhou, Z., Hurtado, J., Kim, K. K., Pickard, R. T., and Kwon, B. S. (1993) J. Immunol. 150, 771-781[Abstract/Free Full Text]
  26. Prasad, K. V. S., Ao, Z., Yoon, Y., Wu, M. X., Rizk, M., Jacquot, S., and Schlossman, S. F. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 6346-6351[Abstract/Free Full Text]
  27. Arch, R. H., and Thompson, C. V. (1998) Mol. Cell. Biol. 18, 558-565[Abstract/Free Full Text]
  28. Jang, I. K., Lee, Z. H., Kim, Y. J., Kim, S. H., and Kwon, B. S. (1998) Biochem. Biophys. Res. Commun. 242, 613-620[CrossRef][Medline] [Order article via Infotrieve]
  29. Saoulli, K., Lee, S. Y., Cannons, J. L., Yeh, W. C., Santana, A., Goldstein, M. D., Bangia, N., DeBenette, M. A., Mak, T. W., Choi, Y., and Watts, T. H. (1998) J. Exp. Med. 187, 1849-1862[Abstract/Free Full Text]
  30. Akiba, H., Nakano, H., Nishinaka, S., Shindo, M., Kobata, T., Atsuta, M., Morimoto, C., Ware, C. F., Malinin, N. L., Wallach, D., Yagita, H., and Okumura, K. (1998) J. Biol. Chem. 273, 13353-13358[Abstract/Free Full Text]
  31. Rothe, M., Sarma, V., Dixit, V. M., and Goeddel, D. V. (1995) Science 269, 1421-1427
  32. Hu, H. M., O'Rourke, K., Boguski, M. S., and Dixit, V. M. (1994) J. Biol. Chem. 269, 30069-30072[Abstract/Free Full Text]
  33. Nakano, H., Oshima, H., Chung, W., Williams-Abbot, L., Ware, C. F., Yagita, H., and Okumura, K. (1996) J. Biol. Chem. 271, 14661-14664[Abstract/Free Full Text]
  34. Takeuchi, M., Rothe, M., and Goeddel, D. V. (1996) J. Biol. Chem. 271, 19935-19942[Abstract/Free Full Text]
  35. Cao, Z., Xiong, J., Takeuchi, M., Kurama, T., and Goeddel, D. V. (1996) Nature 383, 443-446[CrossRef][Medline] [Order article via Infotrieve]
  36. Song, H. Y., Regnier, C. H., Kirschning, C. J., Goeddel, D. V., and Rothe, M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 9792-9796[Abstract/Free Full Text]
  37. Schindler, U., and Baichwal, V. R. (1994) Mol. Cell. Biol. 14, 5820-9796[Abstract]
  38. Mauri, D. N., Ebner, R., Montgomery, R. I., Kochel, K. D., Cheng, T. C., Yu, G. L., Reben, S., Murphy, M., Eisenberg, R. J., Cohen, G. H., Spear, P. G., and Ware, C. F. (1998) Immunity 8, 21-30[Medline] [Order article via Infotrieve]
  39. Cheng, G., Cleary, A. M., Ye, Z.-s., Hong, D. I., Lederman, S., and Baltimore, D. (1995) Science 267, 1494-1498[Medline] [Order article via Infotrieve]
  40. Duckett, C. S., Gedrich, R. W., Gilfillan, M. C., and Thompson, C. B. (1997) Mol. Cell. Biol. 17, 1535-1542[Abstract]
  41. VanArsdale, T. L., VanArsdale, S. L., Force, W. R., Walter, B. N., Mosialos, G., Kieff, E., Reed, J. C., and Ware, C. F. (1996) Proc. Natl. Acad. Sci. U. S. A. 94, 2460-2465[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.